Literature DB >> 9062781

Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.

L Matter1, D Germann, F Bally, K Schopfer.   

Abstract

We have performed age-stratified seroprevalence studies for MMR to evaluate these vaccinations. Serum samples submitted for diagnostic testing were randomly selected for unlinked anonymous panels. IgG antibodies were tested by ELISA and indirect immunofluorescence. In the vaccination cohort (age 1.5 to 6.5 years), seroprevalence attained 80%. For measles and mumps it continued to increase to 95%, while for rubella it declined transiently to 60% between 7 and 12 years of age. We observed no differences according to gender in any age group in 1991-1992. (Semi)quantitative values of the IgG antibodies against all three viruses increased during adolescence, suggesting wild virus circulation. In 1992, MMR vaccination has reached < 80% of the children during their second year of age. Due to previous monovalent measles and mumps vaccinations in pre-school children and due to endemic and epidemic activity, particularly of mumps virus, a trough of the seroprevalence in adolescents was evident only for rubella. MMR vaccination campaigns performed at school since 1987 have increase seroprevalence in this population segment and have probably over-compensated for the expected shift to the right of the seroprevalence curves. A more compulsive implementation of the recommended childhood vaccination schedule and continued efforts at catchup vaccinations during school age especially for rubella are necessary to avoid the accumulation of susceptible young adults during the forthcoming decades.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062781     DOI: 10.1023/a:1007326621525

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  16 in total

1.  [Vaccination and morbidity in Basel school-children (measles, mumps, rubella, chickenpox, cytomegalic inclusion disease)].

Authors:  A Bächlin; R Berger-Hernandez; M Just
Journal:  Soz Praventivmed       Date:  1978-08

Review 2.  Rubella in the United Kingdom.

Authors:  E Miller
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

3.  [Immunization coverage at the start of compulsory school attendance].

Authors:  V Woringer
Journal:  Rev Med Suisse Romande       Date:  1989-05

4.  [New Swiss vaccination schedule].

Authors:  M Just
Journal:  Ther Umsch       Date:  1986-07

5.  [Rubella. epidemiological studies and experiences with an attenuated vaccine ("Cendehill strain")].

Authors:  R Majer
Journal:  Helv Paediatr Acta       Date:  1967-12

6.  An outbreak of mumps in a population partially vaccinated with the Rubini strain.

Authors:  D Germann; A Ströhle; K Eggenberger; C A Steiner; L Matter
Journal:  Scand J Infect Dis       Date:  1996

7.  The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.

Authors:  H Peltola; O P Heinonen; M Valle; M Paunio; M Virtanen; V Karanko; K Cantell
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

8.  The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization.

Authors:  R M Anderson; J A Crombie; B T Grenfell
Journal:  Epidemiol Infect       Date:  1987-08       Impact factor: 2.451

9.  Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.

Authors:  H C Matter; J Cloetta; H Zimmermann
Journal:  J Epidemiol Community Health       Date:  1995-08       Impact factor: 3.710

10.  The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme.

Authors:  L Matter; F Bally; D Germann; K Schopfer
Journal:  Eur J Epidemiol       Date:  1995-06       Impact factor: 8.082

View more
  10 in total

1.  Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease.

Authors:  Kh Muhsen; Y Aboudy; E Mendelson; M S Green; D Cohen
Journal:  Epidemiol Infect       Date:  2007-07-03       Impact factor: 2.451

2.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

3.  Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.

Authors:  C Nicoara; K Zäch; D Trachsel; D Germann; L Matter
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 4.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 5.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

6.  Seroprevalence of neutralizing antibodies to measles virus in a vaccinated population in Iran, 1998.

Authors:  Mazaher Khodabandeh Loo; Farzaneh Sabahi; Horieh Soleimanjdahi; Anooshirvan Kazemnejad; Mohammod Hassan Roustai
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

7.  An outbreak of measles in a prison in Yorkshire, England, December 2012-January 2013.

Authors:  J R Crick; R Firth; S Padfield; A Newton
Journal:  Epidemiol Infect       Date:  2013-08-19       Impact factor: 4.434

8.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

9.  Measles in Saudi Arabia: from control to elimination.

Authors:  Mohamed K M Khalil; Yagob Y Al-Mazrou; Mansour N AlHowasi; Mohamed Al-Jeffri
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

10.  Serostatus of IgG antibody against mumps virus in adult population of Al Madinah Al Munawarah, Saudi Arabia.

Authors:  Waleed H Mahallawi; Mohiadeen M Kurdi; Nadir A Ibrahim
Journal:  Saudi Med J       Date:  2021-08       Impact factor: 1.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.